Loading the records…
Gilbert Cisneros
DemocratCA31•house•Filed Sep 12, 2025
View all of Gilbert Cisneros's trades →47 total filings on record
Gilbert Cisneros (D-CA) sold $15K-$50K of $RAL (Ralliant Corporation Common Stock (RAL) [ST]) on Jul 8, 2025, part of 65 transactions in this filing (35 buys, 30 sells).
Transactions
65
Companies
24
Largest Trade
$15K-$50K
Timing Flags
None
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Trade Day
$48.00
Jul 8, 2025
Current
$72.41
Jun 29, 2026
Change
+50.85%
+$24.41
Trade Day
$87.13
Aug 27, 2025
Current
$51.45
Jun 29, 2026
Change
-40.95%
$-35.68
Trade Day
$57.76
Sep 2, 2025
Current
$156.14
Jun 29, 2026
Change
+170.33%
+$98.38
Trade Day
$36.23
Aug 26, 2025
Current
$41.01
Jun 29, 2026
Change
+13.19%
+$4.78
Trade Day
$45.04
Aug 26, 2025
Current
$24.68
Jun 29, 2026
Change
-45.20%
$-20.36
Trade Day
$146.25
Aug 26, 2025
Current
$85.24
Jun 29, 2026
Change
-41.72%
$-61.01
Showing the 6 largest positions. See every transaction in the table below.
🔒
Sign Up to See More
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access →Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $SMTC | Semtech Corporation - Common Stock (SMTC) [ST] | $1K-$15K | $57.76 | $156.14 | +170.3% | Aug 26, 2025 |
| BUY | $APG | APi Group Corporation Common Stock (APG) [ST] | $1K-$15K | $36.23 | $41.01 | +13.2% | Aug 26, 2025 |
| BUY | $INTA | Intapp, Inc. - Common Stock (INTA) [ST] | $1K-$15K | $45.04 | $24.68 | -45.2% | Aug 26, 2025 |
| BUY | $INTA | Intapp, Inc. - Common Stock (INTA) [ST] | $1K-$15K | $45.04 | $24.68 | -45.2% | Aug 15, 2025 |
| BUY | $WAT | Waters Corporation Common Stock (WAT) [ST] | $1K-$15K | $296.14 | $368.87 | +24.6% | Aug 13, 2025 |
| BUY | $WAT | Waters Corporation Common Stock (WAT) [ST] | $1K-$15K | $296.14 | $368.87 | +24.6% | Aug 12, 2025 |
| BUY | $BBIO | BridgeBio Pharma, Inc. - Common Stock (BBIO) [ST] | $1K-$15K | $46.58 | $72.01 | +54.6% | Aug 8, 2025 |
| BUY | $HESAF | Hermes Intl S A Ordinary Shares (HESAF) [ST] | $1K-$15K | $2,522.13 | $1,861.89 | -26.2% | Aug 7, 2025 |
| BUY | $CAG | ConAgra Brands, Inc. Common Stock (CAG) [ST] | $1K-$15K | $18.80 | $13.98 | -25.6% | Aug 5, 2025 |
| BUY | $HAL | Halliburton Company Common Stock (HAL) [ST] | $1K-$15K | $21.68 | $34.09 | +57.2% | Aug 5, 2025 |
BUY$1K-$15K
$SMTCSemtech Corporation - Common Stock (SMTC) [ST]
$57.76 \u2192 $156.14+170.3%
Aug 26, 2025 \u2022 self
BUY$1K-$15K
$APGAPi Group Corporation Common Stock (APG) [ST]
$36.23 \u2192 $41.01+13.2%
Aug 26, 2025 \u2022 self
BUY$1K-$15K
$INTAIntapp, Inc. - Common Stock (INTA) [ST]
$45.04 \u2192 $24.68-45.2%
Aug 26, 2025 \u2022 self
BUY$1K-$15K
$INTAIntapp, Inc. - Common Stock (INTA) [ST]
$45.04 \u2192 $24.68-45.2%
Aug 15, 2025 \u2022 self
BUY$1K-$15K
$WATWaters Corporation Common Stock (WAT) [ST]
$296.14 \u2192 $368.87+24.6%
Aug 13, 2025 \u2022 self
BUY$1K-$15K
$WATWaters Corporation Common Stock (WAT) [ST]
$296.14 \u2192 $368.87+24.6%
Aug 12, 2025 \u2022 self
BUY$1K-$15K
$BBIOBridgeBio Pharma, Inc. - Common Stock (BBIO) [ST]
$46.58 \u2192 $72.01+54.6%
Aug 8, 2025 \u2022 self
BUY$1K-$15K
$HESAFHermes Intl S A Ordinary Shares (HESAF) [ST]
$2,522.13 \u2192 $1,861.89-26.2%
Aug 7, 2025 \u2022 self
BUY$1K-$15K
$CAGConAgra Brands, Inc. Common Stock (CAG) [ST]
$18.80 \u2192 $13.98-25.6%
Aug 5, 2025 \u2022 self
BUY$1K-$15K
$HALHalliburton Company Common Stock (HAL) [ST]
$21.68 \u2192 $34.09+57.2%
Aug 5, 2025 \u2022 self
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
BillHR5127bullish
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.
Sep 4, 2025
BillHR3838bullish
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
HR3838, the FY2026 NDAA (SPEED Act), authorizes defense procurement and reforms the acquisition system, providing a structural bullish catalyst for prime defense contractors. Despite a sector-wide selloff over the last 30 days (LMT -15.7%, NOC -15.6%, RTX -9.4%), this legislation establishes a spending floor. The bill is currently in the Senate after House passage, with bipartisan momentum supporting final enactment by end of 2025.
Sep 30, 2025
BillHR5301bullish
PIPES Act of 2025
The PIPES Act advancing out of House committee combined with DPA determinations for natural gas and LNG infrastructure creates a clear regulatory tailwind for US midstream. Pipeline operators KMI, WMB, ET, EPD, TRP, and TRGP all show positive 7-day momentum ranging from +0.35% to +5.08%, reflecting growing market conviction that federal policy is now actively enabling pipeline expansion rather than blocking it.
Sep 17, 2025
BillHR5917neutral
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 is an early-stage procedural bill authorizing the President to extend normal trade relations to most countries by waiving the Jackson-Vanik amendment. It authorizes no funding and changes no current tariff levels. Real market data shows $WMT at $130.81 near its 52-week high, with a 30-day gain of 5.25%, and $AAPL up 8.8% in 30 days—indicating that favorable trade expectations are already priced in. The bill faces a long legislative path with no near-term market impact.
Nov 4, 2025
BillS2857neutral
Protecting Free Vaccines Act of 2025
The Protecting Free Vaccines Act of 2025 is an early-stage bill (S.2857) that codifies existing ACIP vaccine coverage mandates through 2030 without expanding coverage, creating new funding, or changing market dynamics. The bill's impact on vaccine manufacturers and insurers is neutral: it removes regulatory uncertainty but provides no growth catalyst. All S&P 500 stocks covered have been declining over the past 30 days, with MRNA down 13.49% in the last week alone. This bill does not alter those trends.
Sep 18, 2025
BillHR5199bullish
Modernizing Rural Physician Assistant and Nurse Practitioner Utilization Act of 2025
HR5199 is an early-stage bill that would allow PAs and NPs to practice independently in rural non-physician-directed clinics under State law, removing a federal Medicare supervision requirement. The bill authorizes zero funding and has a distant effective date of January 2027. For insurers like UNH, CNC, and CI, and hospital operator HCA, the impact is modest — a small reduction in rural facility costs that won't materially move earnings.
Sep 8, 2025
Billneutral
BRISTOW LLC: $32.0M Department of the Interior Contract
This $32.0 million contract to Bristow LLC for helicopter flight services supports offshore energy operations, providing a steady revenue stream for the company. While not transformative, it reinforces Bristow's position in a critical support sector.
Aug 15, 2025
VTOL
BillHR5448bullish
Protecting Free Vaccines Act
The Protecting Free Vaccines Act (HR5448) is an early-stage House bill that would mandate zero-cost-sharing coverage for ACIP-recommended vaccines across Medicare, Medicaid, CHIP, and private insurance until 2030. Vaccine manufacturers like Pfizer and Moderna are structurally positioned to benefit from increased utilization, while health insurers like UnitedHealth face higher claims costs. CVS has mixed exposure as both insurer (Aetna) and vaccine administrator (CVS Pharmacy). The bill is referred to three committees with 72 cosponsors and has a Senate companion bill (S2857), but a long legislative path remains.
Sep 18, 2025
BillHR747bearish
Stop Chinese Fentanyl Act of 2025
HR747 (Stop Chinese Fentanyl Act) is an early-stage House bill expanding sanctions definitions for Chinese entities involved in opioid precursors. The bill has been reported by committee but faces a long legislative path. Market data shows chemicals ($DD, $ECL) are near 30-day lows while logistics ($UPS, $FDX, $CHRW) have rallied 12-15% in the last month, indicating no market pricing of this bill's risk. Impact score is low at 2 because the bill authorizes zero funding, remains early-stage, and would affect a narrow subset of US-China chemical trade.
Sep 3, 2025
BillHR5454bearish
Medicare Advantage Prompt Pay Act
The Medicare Advantage Prompt Pay Act (HR5454) is early-stage legislation that would mandate MA plans to pay 95% of clean claims within 14 days (electronic in-network) or 30 days (other). This eliminates float income and increases administrative costs for MA insurers. Recent rallies in UNH (+3.3% 7-day), HUM (+12.12%), ELV (+8.12%), MOH (+10.8%), and CVS (+6.9%) appear disconnected from this structural headwind.
Sep 18, 2025
Other Filings by Gilbert Cisneros
Free — no credit card
Get the next Cisneros trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.